Titre:
  • Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Auteur:Verset, Gontran; Verslype, Chris; Reynaert, Herwig; Borbath, Ivan; Langlet, Philippe; Vandebroek, A; Peeters, Michel; Houbiers, Ghislain; Francque, S; Arvanitakis, Marianna; Van Laethem, Jean-Luc
Informations sur la publication:British Journal of Cancer, 97, 5, page (582-588)
Statut de publication:Publié, 2007-09
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Hepatocellular carcinoma (HCC)
Octreotide
Somatostatin analogues
Tamoxifen
MeSH keywords:Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Carcinoma, Hepatocellular -- drug therapy -- metabolism -- pathology
Diarrhea -- chemically induced
Female
Humans
Liver Neoplasms -- drug therapy -- metabolism -- pathology
Male
Middle Aged
Multivariate Analysis
Nausea -- chemically induced
Neoplasm Staging
Octreotide -- administration & dosage -- adverse effects
Patient Compliance -- statistics & numerical data
Prognosis
Quality of Life
Survival Analysis
Tamoxifen -- administration & dosage -- adverse effects
Treatment Outcome
alpha-Fetoproteins -- metabolism
Note générale:Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0007-0920
info:doi/10.1038/sj.bjc.6603901
info:pii/6603901
info:scp/34548356811
info:pmid/17687341
PMC2360361